



(51) International Patent Classification:

C07C 233/18 (2006.01) *A61K 31/165* (2006.01)
C07C 231/12 (2006.01) *A61P 25/24* (2006.01)

CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN).

(21) International Application Number:

PCT/CN2011/071910

(74) Agent: **ZHONGZI LAW OFFICE**; 7F, New Era Building, 26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).

(22) International Filing Date:

17 March 2011 (17.03.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201010126254.X 17 March 2010 (17.03.2010) CN

(71) Applicant (for all designated States except US): **LES LABORATOIRES SERVIER** [FR/FR]; 35, Rue de Verdun, 92284 Suresnes Cedex (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SHAN, Hanbin** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **YUAN, Zhedong** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **ZHU, Xueyan** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **ZHANG, Peng** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **PAN, Hongjuan** [CN/CN]; Shanghai Institute of Pharmaceutical Industry, No. 1320, West Beijing Road, Jing'an District, Shanghai 200040 (CN). **YU, Xiong** [CN/


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF



(57) Abstract: An agomelatine hydrochloride hydrate of formula (I), preparation, use, and pharmaceutical composition thereof are provided. Said hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. Using the present method, high purity can be obtained through a simple process, free of any complicated steps. Wherein X is Cl.